In this video, Hong Truong, MD,discusses the takeaways of the study, “Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Truong is a urologic oncology fellow at Memorial Sloan Kettering Cancer Center in New York, New York.
Expert discusses advances, unmet needs across prostate cancer continuum
May 21st 2024“Certainly, there are more and more radioligands coming out not only in prostate cancer, but in other cancers related to urology, and I think that's going to be the next big wave,” says Timothy A. Richardson, MD.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.